<DOC>
	<DOCNO>NCT01074359</DOCNO>
	<brief_summary>This phase 2a , double-blind , placebo-controlled , single-center study . Twenty-one patient qualify study randomly assign either active drug placebo . The study take place Newcastle University . Patients 66 % chance get active drug . Patients require take study treatment orally twice day 28 day . A baseline visit occur within 21 day screen visit . All patient follow 1 week completion study early withdrawal study .</brief_summary>
	<brief_title>Safety Efficacy Study A0001 Patients With A3243G Mitochondrial DNA Point Mutation</brief_title>
	<detailed_description />
	<mesh_term>Neuromuscular Diseases</mesh_term>
	<mesh_term>Tocopherylquinone</mesh_term>
	<criteria>Diagnosis neuromuscular symptom due A3243G mitochondrial DNA point mutation PCR/ATP ratio &lt; 1.9 follow Cardiac MRS screen Any major illness due A3243G mitochondrial DNA point mutation past three month significant ongoing chronic medical illness , especially significant central nervous neurological disease limit capacity carry study Use investigational product within past 30 day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>A3243G Mitochondrial DNA Point Mutation</keyword>
</DOC>